Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
DPP-4 inhibitors
GLP-1 receptor agonists
thyroid cancer
type 2 diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
revised:
28
08
2023
received:
13
07
2023
accepted:
04
09
2023
pubmed:
22
9
2023
medline:
22
9
2023
entrez:
22
9
2023
Statut:
ppublish
Résumé
To determine the potential association between the use of either glucagon-like peptide-1 receptor agonists (GLP-1RAs) or dipeptidyl peptidase-4 (DPP-4) inhibitors, and the risk of thyroid cancer in individuals with type 2 diabetes. This population-based cohort study used claims data from the Korean National Health Insurance Database, 2014-2020. Two distinct cohorts were established to compare each incretin-based drug with sodium-glucose cotransporter-2 (SGLT2) inhibitors, chosen as active comparators because of their previous non-association with thyroid cancer, and their common usage as add-on therapy to metformin along with GLP-1RAs and DPP-4 inhibitors. The first cohort included 21 722 new users of GLP-1RAs and 326 993 new users of SGLT2 inhibitors, whereas the second cohort included 904 300 DPP-4 inhibitor new users and 112 017 SGLT2 inhibitor new users. The outcome was the time to incident thyroid cancer. Weighted Cox proportional models were used to estimate hazard ratios of thyroid cancer incidence associated with incretin-based drugs of interest. The use of GLP-1RAs was not associated with an increased risk of thyroid cancer (weighted hazard ratio 0.98, 95% confidence interval 0.62-1.53) compared with that of SGLT2 inhibitors. Using DPP-4 inhibitors was also not associated with an increased risk of thyroid cancer (0.95, 0.79-1.14) compared with that of SGLT2 inhibitors. No significant effect modifications were observed across subgroup analyses. Sensitivity analyses, including alternative outcome definition analysis of medullary thyroid cancer, were consistent with the primary analysis results. GLP-1RAs and DPP-4 inhibitors were not associated with an increased risk of thyroid cancer in individuals with type 2 diabetes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
108-117Subventions
Organisme : Ministry of Food and Drug Safety
ID : 21153MFDS607
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of Care in Diabetes-2023. Diabetes Care. 2022;46(Supplement_1):S140-S157.
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like Peptide-1-based therapies. Gastroenterology. 2011;141(1):150-156.
Wang J, Kim CH. Differential risk of cancer associated with glucagon-like Peptide-1 receptor agonists: analysis of real-world databases. Endocr Res. 2022;47(1):18-25.
Tseng CH. Sitagliptin use and thyroid cancer risk in patients with type 2 diabetes. Oncotarget. 2016;7(17):24871-24879.
Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473-1486.
Byrd RA, Sorden SD, Ryan T, et al. Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents. Endocrinology. 2015;156(7):2417-2428.
Bulchandani D, Nachnani JS, Herndon B, et al. Effect of exendin (exenatide)-GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model. Eur J Pharmacol. 2012;691(1-3):292-296.
Nauck MA, Jensen TJ, Rosenkilde C, Calanna S, Buse JB. Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial. Diabetes Care. 2018;41(8):1663-1671.
Guo X, Yang Q, Dong J, Liao L, Zhang W, Liu F. Tumour risk with once-weekly glucagon-like Peptide-1 receptor agonists in type 2 diabetes mellitus patients: a systematic review. Clin Drug Investig. 2016;36(6):433-441.
Zhao M, Chen J, Yuan Y, et al. Dipeptidyl Peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Sci Rep. 2017;7(1):8273.
Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46(2):384-390.
Thompson CA, Stürmer T. Putting GLP-1 RAs and thyroid cancer in context: additional evidence and remaining doubts. Diabetes Care. 2022;46:249-251.
Corrao G, Mancia G. Research strategies in treatment of hypertension: value of retrospective real-life data. Eur Heart J. 2022;43(35):3312-3322.
Shi N, Shi Y, Xu J, et al. SGLT-2i and risk of malignancy in type 2 diabetes: a meta-analysis of randomized controlled trials. Front Public Health. 2021;9:668368.
Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl Peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992-1019.
Cheol Seong S, Kim YY, Khang YH, et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2017;46(3):799-800.
Park E, Jeon S, Lee S, Lee J, Choi D. Report of the evaluation for validity of discharged diagnoses in Korean health insurance database. Health Insurance Review and Assessment Service. HIRA OAK repository; 2017. https://repository.hira.or.kr/handle/2019.oak/730
Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut. 2022;71(1):16-24.
Jeon MJ, Kang YE, Moon JH, et al. Corrigendum: Correction of Acknowledgments. Protocol for a Korean multicenter prospective cohort study of active surveillance or surgery (KoMPASS) in papillary thyroid microcarcinoma. Endocrinol Metab. 2022;37(1):181-182.
Pottegard A, Friis S, Sturmer T, Hallas J, Bahmanyar S. Considerations for Pharmacoepidemiological studies of drug-cancer associations. Basic Clin Pharmacol Toxicol. 2018;122(5):451-459.
American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125-S143.
Kang HY, Kim I, Kim YY, Bahk J, Khang YH. Income differences in screening, incidence, postoperative complications, and mortality of thyroid cancer in South Korea: a National Population-Based Time Trend Study. BMC Cancer. 2020;20(1):1096.
Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657.
Bogović Crnčić T, Ilić Tomaš M, Girotto N, Grbac IS. Risk factors for thyroid cancer: what do we know so far? Acta Clin Croat. 2020;59(Suppl 1):66-72.
Bethel MA, Patel RA, Thompson VP, et al. Changes in serum calcitonin concentrations, incidence of medullary thyroid carcinoma, and impact of routine calcitonin concentration monitoring in the EXenatide study of cardiovascular event lowering (EXSCEL). Diabetes Care. 2019;42(6):1075-1080.
Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide-the FDA's review of a new antidiabetic therapy. N Engl J Med. 2010;362(9):774-777.
Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW. Glucagon like Peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97(1):121-131.
Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog liraglutide. J Clin Endocrinol Metab. 2011;96(3):853-860.
Jung MJ, Kwon SK. Expression of glucagon-like Peptide-1 receptor in papillary thyroid carcinoma and its clinicopathologic significance. Endocrinol Metab. 2014;29(4):536-544.
He L, Zhang S, Zhang X, Liu R, Guan H, Zhang H. Effects of insulin analogs and glucagon-like Peptide-1 receptor agonists on proliferation and cellular energy metabolism in papillary thyroid cancer. Onco Targets Ther. 2017;10:5621-5631.
Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC. Glucagon-like-peptide-1 receptor expression in Normal and diseased human thyroid and pancreas. Mod Pathol. 2015;28(3):391-402.
Boess F, Bertinetti-Lapatki C, Zoffmann S, et al. Effect of GLP1R agonists Taspoglutide and liraglutide on primary thyroid C-cells from rodent and man. J Mol Endocrinol. 2013;50(3):325-336.
Aschebrook-Kilfoy B, Sabra MM, Brenner A, et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP diet and health study. Thyroid. 2011;21(9):957-963.
Ock S, Ahn J, Lee SH, et al. Thyrocyte-specific deletion of insulin and IGF-1 receptors induces papillary thyroid carcinoma-like lesions through EGFR pathway activation. Int J Cancer. 2018;143(10):2458-2469.
Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer. 2020;20(11):629-644.
Vigneri R, Sciacca L, Vigneri P. Rethinking the relationship between insulin and cancer. Trends Endocrinol Metab. 2020;31(8):551-560.
Lund JL, Richardson DB, Stürmer T. The active comparator, new user study Design in Pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2(4):221-228.
Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920.